CADTH Canadian Drug Expert Committee recommendation: Nitisinone (MDK-Nitisinone -- mendeliKABs inc.) indication : the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine
The CADTH Canadian Drug Expert Committee (CDEC) recommends that nitisinone (MDK-Nitisinone) be reimbursed for the treatment of adult and pediatric patients with HT-1 in combination with dietary restriction of tyrosine and phenylalanine, if the following criterion and conditions are met: for use in p...
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, April 2018
|
Edition: | Version 1.0 |
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that nitisinone (MDK-Nitisinone) be reimbursed for the treatment of adult and pediatric patients with HT-1 in combination with dietary restriction of tyrosine and phenylalanine, if the following criterion and conditions are met: for use in patients with an established diagnosis of HT-1. The drug is prescribed by a physician with experience in the diagnosis and management of HT-1. The total cost of treatment with nitisinone (MDK-Nitisinone) should not exceed the drug plan cost of other nitisinone products |
---|---|
Item Description: | "Final." |
Physical Description: | 1 PDF file (8 pages) |